Eosinopenia is a reliable marker of severe disease and unfavourable outcome in patients with COVID‐19 pneumonia

• DOI: 10.1111/ijcp.14047
• Publication Date: 2021-01-26T18:12:20Z
• Authors: Massimo Cazzaniga; Luca A. M. Fumagalli; Luciano D'angelo; Mario Cerino; Giulia Bonfanti; Riccardo M. Fumag...; Gianpaolo Schiavo; Cristina Lorini; Elisa Lainu; Sabina Terragni; Marco Chiarelli; Claudio Scarazzati; Claudio Bonato; Mauro Zago
• Keywords: Eosinopenia; Viral Pneumonia

Viral pneumonia is the most relevant clinical presentation of COVID-19 which may lead to severe acute respiratory syndrome and even death. Eosinopenia was often noticed in patients with pneumonia, but its role poorly investigated. The aim present study investigate characteristics outcomes eosinopenia.We revised records consecutive admitted our ER-COVID-19 area order compare without eosinopenia. We considered following outcomes: 4-weeks survival; need for intensive support; hospital discharge.Out first 107 a positive nasopharyngeal swab, 75 showed undetectable eosinophil count (absolute eosinopenia). At 4 weeks, 38 (38.4%) had required treatment, 25 (23.4%) deceased 42 (39.2%) were discharged. Compared absolute eosinopenia, eosinopenia higher treatment (49.3% vs 13.3%, P < .001), mortality (30.6% 6.2%, .006) lower rate discharge (28% 65.6%, .001). Binary logistic regression analyses including neutrophil, lymphocyte, eosinophil, basophil monocyte counts that an independent factor associated mortality, support discharge.Absolute might be used as marker discriminate unfavourable prognosis.